HC Wainwright Issues Pessimistic Forecast for ANIP Earnings

Key Points

• HC Wainwright lowered its Q3 2026 EPS forecast for ANI Pharmaceuticals to $1.66 from $1.94, and estimates FY2026 earnings at $7.78 per share versus the broader consensus of $8.03.
• ANI’s latest quarter exceeded expectations, with EPS of $2.21 versus the $2.04 consensus and revenue of $266.04 million, up 25.8% year over year. The company maintained FY2026 EPS guidance of $9.19–$9.69.
• Analyst sentiment remains mixed but leans positive: four analysts rate the stock Buy and four rate it Hold, producing a “Moderate Buy” consensus and an average price target of $105.83, compared with a recent share price of $76.87.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) - Research analysts at HC Wainwright cut their Q3 2026 EPS estimates for shares of ANI Pharmaceuticals in a research report issued to clients and investors on Tuesday, August 11th. HC Wainwright analyst B. Folkes now forecasts that the specialty pharmaceutical company will post earnings per share of $1.66 for the quarter, down from their prior forecast of $1.94. The consensus estimate for ANI Pharmaceuticals' current full-year earnings is $8.03 per share. HC Wainwright also issued estimates for ANI Pharmaceuticals' Q4 2026 earnings at $2.58 EPS and FY2026 earnings at $7.78 EPS.

ANIP has been the subject of a number of other research reports. Wall Street Zen lowered ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 8th. Canaccord Genuity Group reduced their price target on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a "hold" rating for the company in a research report on Monday, August 10th. Zacks Research downgraded shares of ANI Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 14th. Weiss Ratings lowered shares of ANI Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Tuesday, August 11th. Finally, Guggenheim lowered their price objective on ANI Pharmaceuticals from $124.00 to $119.00 and set a "buy" rating on the stock in a report on Monday, August 10th. Four investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $105.83.

ANI Pharmaceuticals Trading Up 1.1%

NASDAQ:ANIP opened at $76.87 on Wednesday. The company has a market capitalization of $1.77 billion, a P/E ratio of 16.57 and a beta of 0.44. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99. ANI Pharmaceuticals has a 12 month low of $70.15 and a 12 month high of $99.50. The firm has a fifty day simple moving average of $80.65 and a 200-day simple moving average of $78.97.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.04 by $0.17. The business had revenue of $266.04 million for the quarter, compared to analyst estimates of $260.13 million. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. ANI Pharmaceuticals's revenue for the quarter was up 25.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.80 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Arrowstreet Capital Limited Partnership acquired a new stake in shares of ANI Pharmaceuticals in the 3rd quarter worth $32,992,000. Ranger Investment Management L.P. acquired a new position in shares of ANI Pharmaceuticals during the 2nd quarter valued at about $28,406,000. Deutsche Bank AG acquired a new position in shares of ANI Pharmaceuticals during the 2nd quarter valued at about $26,775,000. Balyasny Asset Management L.P. grew its holdings in shares of ANI Pharmaceuticals by 2,785.7% in the third quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company's stock valued at $26,211,000 after purchasing an additional 276,233 shares during the period. Finally, William Blair Investment Management LLC purchased a new stake in shares of ANI Pharmaceuticals in the second quarter valued at about $21,372,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at ANI Pharmaceuticals

In related news, Director Thomas Haughey sold 2,000 shares of the company's stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $80.88, for a total transaction of $161,760.00. Following the completion of the sale, the director owned 38,878 shares of the company's stock, valued at approximately $3,144,452.64. This represents a 4.89% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Stephen P. Carey sold 2,850 shares of the company's stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $81.36, for a total transaction of $231,876.00. Following the sale, the chief financial officer directly owned 174,693 shares of the company's stock, valued at approximately $14,213,022.48. This represents a 1.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 18,987 shares of company stock valued at $1,546,405 over the last ninety days. 8.10% of the stock is currently owned by corporate insiders.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source